AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$BDTX

Black Diamond: Q3 Earnings Snapshot

Black Diamond Therapeutics (BDTX) reported a Q3 loss of $10 million, or 17 cents per share, missing analyst expectations of a 3-cent loss per share. Shares closed at $1.86, down from $3.89 a year ago.

Original reporting
finance.yahoo.com
Published Nov 10, 2026, 11:37 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 11:52 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Black Diamond: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$BDTXBearishMed
01

Why it matters

The unexpected loss may prompt short sellers and cause the stock to trade lower in after-hours trading.

02

Market read

Microcap biotech earnings miss with limited broader market impact.

03

What to watch

Potential pipeline developments or upcoming clinical data not mentioned could offset the earnings miss.

Relevance 6/10Novelty 6/10Timing: after-hours

Background

The article is an automated earnings snapshot generated from Zacks data, providing the latest quarterly loss figures for Black Diamond Therapeutics.

Company-level read

Ticker impact

$BDTXBearishHigh confidence
Context

Black Diamond Therapeutics reported a Q3 loss of $10M, 17 cents per share versus expectations of a 3 cent loss.

Expected impact

likely downside as results miss estimates

Evidence & confidence

The loss exceeds analyst expectations, and the share price fell to $1.86 from $3.89 a year ago.

Market effects

Sector

Biotech sector may see modest pressure as a microcap earnings miss highlights valuation risks.

Regional

Limited to U.S. biotech investors; no broader market effect.

Global

Low global relevance due to small company size.

Counterpoint

What could challenge this read

Some investors may view the steep price decline as a buying opportunity if they believe the loss is temporary.

Key entities

  • company
    Black Diamond Therapeutics, Inc.

    Biotech firm reporting Q3 earnings.

Read at source← All news

Related articles

$BDTXMedAI 9/10

Black Diamond Therapeutics (BDTX) Reports Updated Phase 2 Results and FDA Feedback

Black Diamond Therapeutics (BDTX) reported updated Phase 2 results for silevertinib, showing strong CNS activity and longer progression-free survival than current treatments. The FDA supports a potential registration path for all first-line EGFR-NCM NSCLC patients. The company has $102.0 million in cash to fund operations into 2028. BDTX will host an investor call and participate in a conference.

tradingview.com
$BDTXHigh

Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L…

Black Diamond Therapeutics, Inc. (BDTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update • Updated Phase 2 results demonstrate robust CNS activity, including 86% CNS-ORR

SEC EDGAR 8-K